Affordability of Medicines a Top Priority for EHA: Toward a Fair Pricing Model for Innovative Medicines.
作者信息
Hagenbeek Anton, Engert Andreas, Kapitein Peter, Doeswijk Robin
机构信息
Academic Medical Center University of Amsterdam, Amsterdam, The Netherlands.
University Hospital of Cologne, Cologne, Germany.
出版信息
Hemasphere. 2017 Dec 20;1(1):e12. doi: 10.1097/HS9.0000000000000012. eCollection 2017 Dec.
Abstract
摘要
相似文献
1
Affordability of Medicines a Top Priority for EHA: Toward a Fair Pricing Model for Innovative Medicines.药品可负担性是欧洲血液学协会的首要任务：迈向创新药物的公平定价模式。
Hemasphere. 2017 Dec 20;1(1):e12. doi: 10.1097/HS9.0000000000000012. eCollection 2017 Dec.
2
Fair Pricing of Innovative Medicines: An EHA Position Paper.创新药物的公平定价：欧洲血液学协会立场文件
Hemasphere. 2020 Sep 30;4(5):e488. doi: 10.1097/HS9.0000000000000488. eCollection 2020 Oct.
3
Availability and affordability of priority life-saving medicines for under-five children in health facilities of Tigray region, northern Ethiopia.提格雷地区（埃塞俄比亚北部）卫生机构中 5 岁以下儿童优先救命药品的可及性和可负担性。
BMC Pregnancy Childbirth. 2018 Nov 29;18(1):464. doi: 10.1186/s12884-018-2109-2.
4
Access and Affordability of Medicines in Malaysia: Need for a National Pricing Policy.马来西亚的药品可及性和可负担性：需要国家定价政策。
Appl Health Econ Health Policy. 2019 Oct;17(5):641-654. doi: 10.1007/s40258-019-00480-9.
5
Availability and Affordability of Drugs With a Conditional Approval by the European Medicines Agency; Comparison of Korea With Other Countries and the Implications.欧洲药品管理局有条件批准药品的可及性与可负担性；韩国与其他国家的比较及启示
Front Pharmacol. 2018 Sep 3;9:938. doi: 10.3389/fphar.2018.00938. eCollection 2018.
6
The Availability, Pricing, and Affordability of Essential Diabetes Medicines in 17 Low-, Middle-, and High-Income Countries.17个低收入、中等收入和高收入国家基本糖尿病药物的可及性、定价与可负担性
Front Pharmacol. 2019 Nov 19;10:1375. doi: 10.3389/fphar.2019.01375. eCollection 2019.
7
Policy approaches to improve availability and affordability of medicines in Mexico - an example of a middle income country.墨西哥提高药品可及性和可负担性的政策措施——一个中等收入国家的实例
Global Health. 2017 Aug 1;13(1):53. doi: 10.1186/s12992-017-0281-1.
8
New business models for research and development with affordability requirements are needed to achieve fair pricing of medicines.为实现药品公平定价，需要具备可承受性要求的新型研发商业模式。
BMJ. 2020 Jan 13;368:l4408. doi: 10.1136/bmj.l4408.
9
[Risk sharing methods in middle income countries].[中等收入国家的风险分担方法]
Acta Pharm Hung. 2012;82(1):43-52.
10
Evaluating the impact of the single exit price policy on a basket of originator medicines in South Africa from 1999 to 2014 using a time series analysis.利用时间序列分析评估南非 1999 年至 2014 年单一出口价格政策对一篮子原研药品的影响。
BMC Health Serv Res. 2019 Aug 16;19(1):576. doi: 10.1186/s12913-019-4403-8.
引用本文的文献
1
Fair Pricing of Innovative Medicines: An EHA Position Paper.创新药物的公平定价：欧洲血液学协会立场文件
Hemasphere. 2020 Sep 30;4(5):e488. doi: 10.1097/HS9.0000000000000488. eCollection 2020 Oct.
2
Here to Stay: Biosimilars in Hematology.常驻于此：血液学中的生物类似药
Hemasphere. 2019 Nov 19;3(6):e323. doi: 10.1097/HS9.0000000000000323. eCollection 2019 Dec.
本文引用的文献
1
Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues After Approval.研发一种抗癌药物上市的支出及获批后的收入。
JAMA Intern Med. 2017 Nov 1;177(11):1569-1575. doi: 10.1001/jamainternmed.2017.3601.
2
Economic burden of malignant blood disorders across Europe: a population-based cost analysis.欧洲恶性血液疾病的经济负担：基于人群的成本分析。
Lancet Haematol. 2016 Aug;3(8):e362-70. doi: 10.1016/S2352-3026(16)30062-X. Epub 2016 Jul 22.
Zotero 插件